Monoprost (Latanoprost)

Latanoprost, the active ingredient in Monoprost, is a prostaglandin analog presented as a eye drops for ocular use. It treats primary open-angle glaucoma and ocular hypertension in adults.\n\nGNH India supplies Monoprost as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Monoprost is a prostaglandin analog used to lower intraocular pressure in glaucoma‑related conditions.\n\nPrimary open-angle glaucoma: reduces intraocular pressure to slow disease progression.\nOcular hypertension: lowers eye pressure to prevent development of glaucoma.

Common Side Effects:\n- Eye irritation or discomfort\n- Redness of the conjunctiva\n- Increased eyelash growth (hypertrichosis)\n- Darkening of the iris or peri‑ocular skin\n- Blurred vision\n\nSerious or Rare Side Effects:\n- Uveitis or intraocular inflammation\n- Macular edema leading to visual disturbance\n- Severe allergic reaction with swelling or pain\n- Sudden loss of vision\n- Persistent eye pain or photophobia

Before initiating therapy, consider the following precautions.\n\nMonitor intraocular pressure: ensure target reduction is achieved.\nAssess for ocular inflammation: avoid use during active uveitis.\nAvoid use in patients with active ocular infection.\nCaution in patients with a history of uveitis or ocular surgery.\nPregnancy and lactation: consult prescriber as safety data are limited.\nStore at room temperature: keep in the original container, protect from light and moisture.

Latanoprost may interact with other ophthalmic agents.\n\nMajor Interactions (Avoid):\n- Concomitant use with other prostaglandin analogs may cause additive pressure lowering and increased ocular side effects.\n- Use with non‑steroidal anti‑inflammatory eye drops may diminish latanoprost efficacy.\n\nModerate Interactions (Monitor Closely):\n- Beta‑blocker eye drops may produce additive intraocular pressure reduction.\n- Systemic carbonic anhydrase inhibitors can enhance pressure‑lowering effect.\n- Topical corticosteroids may reduce prostaglandin activity, requiring monitoring.